Member Info for MIKODX

Guy's cup is always half empty.

Peel Hunt now owns 33% of the total shares. There should be an announcement stating whether or not they have a vested interest in the company, they're supposed to state what their intentions are. Maybe we will get some more news on that, or maybe PEEL Hunt are just looking to make a return on their investment. We'll see.

Also further proof that you can't trust these charts, they are highly inaccurate.

The market without doubt is corrupt. Just checked on a stock that I've owned since 2021, so long ago I'd almost forgotten about it. I still have the receipt for that stock. I bought it at a cost of 79p. However, when I check on LSE and Google charts, it shows 52p as being the highest SP in the company's history. Further proof the market is indeed corrupt.

We believe FDA authorization, positive utility and outcomes data, our physician and patient education programs, and comprehensive reimbursement puts us on a path towards kidneyintelX.dkd becoming broadly used across the United States among the 14 million Americans with diabetic kidney disease, and ultimately within the global market of 850 million people with chronic kidney disease. We are proud of the rapid pace of these achievements just five years from our company’s inception.

Our real-world evidence data is comprehensive and shows clear benefit. With FDA De Novo marketing authorization in June, kidneyintelX.dkd will become available commercially later in this financial year and we expect to see growth in adoption. The social need could not be higher to establish the innovative preventative medicine strategies that KidneylntelX technology enables at the front-end of diabetes and kidney disease.

During fiscal 2023 over 5,000 KidneylntelX tests were performed, which was up 55% from the prior year. We expect a meaningful increase in total tests during the remainder of fiscal 2024, building on quarterly test volumes of about 1,200 during fiscal 2023 and through first quarter of 2024. More than half of these during the first quarter of 2024 thus far are revenue generating, with a set of the Mount Sinai clinical trial tests no longer billable following last spring’s transition to full commercial payment at the hospital system. We are encouraged by the continued adoption by physicians beyond Mount Sinai. With the launch of the FDA-authorized kidneyintelX.dkd expected later this fiscal year, the enhancement of our direct to physician sales force, and new hospital partners such as Atrium / Wake Forest commencing commercial testing before year-end, we expect to see accelerating billable testing volume growth.

Https://www.nice.org.uk/news/articles/nice-launches-second-consultation-on-genetic-testing-to-guide-treatment-after-a-stroke

Back then, we had 63M shares in issue, giving us a market value of 40M. A 40M MCAP in today's money, gives us an SP of 7-8p.

The financial mess.

Not surprised, looks like a crap company.

Don't people read the RNS's? Just a few weeks back they announced that they've expanded to a further five UK Hospitals in Greater Manchester which will generate in excess of 100K for the company. Although the expansion is slow, it is in progress. We don't need to wait for another Govt to take over, GDR already have their foot in the door.

Https://www.nice.org.uk/news/article/testing-could-help-prevent-further-strokes-in-people-with-gene-variant

I would say 12 months will give us a clearer picture of where this company is heading. Within that time we will see how many more sites adopt the MT-RNR1 test, and also whether or not the test receives full approval. We will also find out in July whether the CYP2C19 test receives NICE reccomendation, and whether or not it receives full approval next year. Positive news from either or both, will massively increase the value of the company.

Been here three years now, feels a lot longer. They say you should give your investments five years at least, but with AIM I prefer to take the big profits when they come and run, dont like to be in them too long unless they really have a unique product or service. Then in others the price drops, like GDR, and your trapped. Averaging down is the only way to recoup some or all of your losses. Learnt a harsh lesson with this Share, wont be making that mistake again.

I've been here a long time too, but I believe in the company which is why I'm still here, and to recover my losses of course..

System - If you get out at 7p you'll be kicking yourself. With FDA and CYP2C19-ID news still to come, and with further hospitals adopting MT-RNR1, this will easily surpass 15p. Have a bit more faith.

Tiger16 - 543M are the new shares in issue, have you been asleep all this time?

Prion25 - I'm with Iwebsharedaling, owned by Halifax, and part of the Lloyds Banking Group.

Checked my share account yesterday and saw that there's still a seperate line for the open offer shares. I tried a dummy sell and got a message that the shares couldn't be sold. Called up my broker to find out why not, and they told me that the shares haven't actually gone through yet, and that once it does it will be consolidated with my existing shares and show as one single entry for all my GDR shares. She also said that there's a possibility that I may not get all the shares I requested and that whatever I dont get, the differnce will be refunded back into my account. So anyone having the same, this is the reason.

Lets also not forget, end of June is end of year results. I can see this slowly rising once the results are out there on the market. Expecting real positive news and an improvement on sales. If your not in this yet, you'd better get in now, it will rise from these levels. With 543M shares in isue, will this fly like it used? This share is known to move rapidly when it takes off, will be interesting to see if it still does with more shares on the market.

So the dilution has gone through and it looks like the capital raise has been priced into the MCAP as well. It’s s good to see the dilution hasn’t taken us below the penny mark. We should be able to build from here. It could go either way now leading up to the stroke news. It could drop a bit or it could start to rise, that all depends on what type of news is coming. I’m expecting positive news so I’m expecting a rise leading up to it. Interesting month coming up.

Whatever they propose and that's if they propose, they would have to run it past shareholders first. Any low ball offers would be straight away rejected.